Andrew L. Schwartz focuses on complex commercial, corporate and securities litigation, and represents clients on a wide range of matters, from class action litigations to privately negotiated resolutions of complicated disputes. Andrew frequently represents private and public corporations, venture capital funds, investment banks, real estate organizations, corporate directors and individuals, and institutional investors – including sovereign wealth funds, family offices, mutual funds, banks, hedge funds, labor union and pension funds – in sophisticated commercial disputes in federal and state courts. He also has significant experience defending companies in litigation arising from antitrust disputes, and is actively involved in the evolving legal landscape surrounding blockchain and distributed ledger technologies.
Andrew is also currently representing Jewish and Israeli students at New York University, Columbia, the University of Pennsylvania and Harvard, in federal courts in the Southern District of New York, Eastern District of Pennsylvania, and the District of Massachusetts, respectively, concerning allegations that the universities tolerate and enable hostile antisemitic educational environments, including pervasive acts of discrimination, harassment and intimidation in violation of Title VI of the Civil Rights Act of 1964.
Andrew has been recognized by The Legal 500, by Benchmark Litigation as a Future Star and on its 40 & Under List, by Super Lawyers as a Rising Star and by Best Lawyers on its Ones to Watch list.
Work Highlights:
- Teva Pharmaceuticals and its individual directors and officers in defense of one of the largest securities class actions in recent history as well as the more than 20 related direct actions, filed on behalf of more than 75 opt-out plaintiffs. The class action was settled in 2022 within insurance limits and the opt-out litigations are ongoing.
- Eros International. Successfully settled putative securities class action in the District of New Jersey on behalf of the company’s former Chief Financial Officer. Following a decision dismissing nearly all of the claims in the case, the lead plaintiff filed an amended complaint, which the CFO separately moved to dismiss.
- A cannabis fintech startup in the Northern District of Illinois pursuing claims of fraud and breach of contract concerning an alleged catch-and-kill scheme.
- The founders and former shareholders of a private company, in New Jersey state court, in defense of allegations of fraud and breach of the share purchase agreement.
- An Israeli company in successfully settling insurance related claims in the American Arbitration Association’s International Centre for Dispute Resolution.
- Valeant Pharmaceuticals Opt-Out Litigation. On behalf of several mutual funds, a public pension plan, and other institutional investors, pursuing direct securities fraud claims against Valeant, arising from Valeant’s improper accounting and billions of dollars of fraud-related losses.
Updated July 2024
